0001193125-26-213466
SEC filingBioAge Labs reported Q1 revenue of $2.8M, up 91% year-over-year from collaboration progress, while operating losses widened to -$25.4M due to increased research and development investments as primary capital uses.
BioAge Labs, Inc. (BIOA) reported Q1 FY2026 results reflecting revenue growth alongside widening losses from intensified R&D investments. Revenue increased 91.0% to $2.8M from $1.5M in Q1 FY2025, attributable to collaboration progress that forms part of the company's topline. This growth occurred as the business continues to prioritize research and development services, compensation, and related expenses as primary uses of capital, consistent with management commentary in Item 2.
Operating income deteriorated to -$25.4M from -$16.4M year-over-year, a -54.3% change, resulting in an operating margin of -915.4%. This reflects accelerated spending on R&D and general overhead costs to support ongoing operations, as general and administrative expenses are expected to rise with business expansion for continued research activities, including potential future clinical trials. Net income followed suit, reaching -$22.3M compared to -$12.9M last year (-72.1% change), with diluted EPS at -$0.52 versus -$0.36 (-44.4%). These dynamics underscore the company's focus on funding research and development amid pre-revenue clinical stage operations typical for biopharma.